Triumvira Appoints Teresa McRoberts as Chief Financial Officer and Announces Senior Level Promotions

April 26, 2021

AUSTIN, Texas & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics (“Triumvira” or the “Company”), a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced the appointment of Teresa McRoberts as Chief Financial Officer. The Company also announced the promotion of Andreas Bader, Ph.D. to Chief Scientific Officer and Jon Irvin to Senior Vice President of Finance. “We are pleased to welcome Teresa to our management team as we continue to advance our platform of novel T cell therapies toward the clinic. Teresa brings strong expertise in financial strategy and capital markets across the healthcare sector which will be invaluable as we enter our next phase of growth,” said Paul Lammers, M.D., M.Sc., President and CEO of Triumvira. “Both Andy and Jon have been integral to the rapid growth of Triumvira and we are also excited to announce their promotions today. Andy has played an instrumental role in shaping our scientific strategy with a track record of taking research programs from the discovery stage into the clinic, and Jon has played a critical role in guiding our financial strategy to date as we’ve quickly scaled up our company.”